Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective
Kim P. C. Kuypers, Eef L. Theunissen, Janelle H. P. van Wel, Elizabeth B. de Sousa Fernandes Perna, A.M.W. Linssen, Anke Sambeth, Benjamin G. Schultz, Johannes G. Ramaekers
PLoS One February 23, 2016 DOI: 10.1371/journal.pone.0149438 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Pooled analysis of experimental studies with placebo control Placebo-controlled Peer reviewed |
|---|---|
| Sample size | 130 |
| Population | Ecstasy users and healthy drug-naïve controls |
| Topics | MDMA |
| Keywords | Memory impairment Verbal memory Placebo Neuropsychology Verbal learning Short-term memory Audiology Cognition Working memory |
| Citations | 23 |
| Key findings | Verbal memory performance of Ecstasy users during abstinence does not differ from that of healthy controls, with substantial evidence for no long-term clinically deficient memory. |
Abstract
Background: Ecstasy use has been associated with short-term and long-term memory deficits on a standard Word Learning Task (WLT). The clinical relevance of this has been debated and is currently unknown. The present study aimed at evaluating the clinical relevance of verbal memory impairment in Ecstasy users. To that end, clinical memory impairment was defined as decrement in memory performance that exceeded the cut-off value of 1.5 times the standard deviation of the average score in the healthy control sample. The primary question was whether being an Ecstasy user (E-user) was predictive of having clinically deficient memory performance compared to a healthy control group.
Methods: WLT data were pooled from four experimental MDMA studies that compared memory performance during placebo and MDMA intoxication. Control data were taken from healthy volunteers with no drug use history who completed the WLT as part of a placebo-controlled clinical trial. This resulted in a sample size of 65 E-users and 65 age- and gender-matched healthy drug-naïve controls. All participants were recruited by similar means and were tested at the same testing facilities using identical standard operating procedures. Data were analyzed using linear mixed-effects models, Bayes factor, and logistic regressions.
Results: Findings were that verbal memory performance of placebo-treated E-users did not differ from that of controls, and there was substantial evidence in favor of the null hypothesis. History of use was not predictive of memory impairment. During MDMA intoxication of E-users, verbal memory was impaired.
Conclusion: The combination of the acute and long-term findings demonstrates that, while clinically relevant memory impairment is present during intoxication, it is absent during abstinence. This suggests that use of Ecstasy/MDMA does not lead to clinically deficient memory performance in the long term. Additionally, it has to be investigated whether the current findings apply to more complex cognitive measures in diverse 'user categories' using a combination of genetics, imaging techniques and neuropsychological assessments.
Comparable studies
Other randomized controlled trials on MDMA, most cited first.
Citations in the library
Cited by 14
- Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline Frontiers in Psychiatry September 12, 2019
- Safety pharmacology of acute MDMA administration in healthy subjects Journal of Psychopharmacology February 21, 2017
- Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine ACS Chemical Neuroscience July 12, 2018
- Understanding the Mechanisms of Action and Effects of Drugs of Abuse. Molecules June 24, 2023
- MDMA and MDMA-Assisted Therapy. American Journal of Psychiatry 2025
and 9 more in the library
Cites 21
- Memory impairment in abstinent MDMA ("Ecstasy") users Neurology December 1, 1998
- Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits Journal of Psychopharmacology 1998
- Is MDMA (‘Ecstasy’) Neurotoxic in Humans? An Overview of Evidence and of Methodological Problems in Research Neuropsychobiology 2000
- MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Frontiers in Genetics 2012
- No Evidence that MDMA-Induced Enhancement of Emotional Empathy Is Related to Peripheral Oxytocin Levels or 5-HT1a Receptor Activation PLoS One June 27, 2014
and 16 more in the library